Testicular Cancer Treatment

Retroperitoneal Lymph Node Dissection (RPLND)

Surgical Removal of Retroperitoneal Lymph Nodes for Testicular Cancer

3–5 Hours PROCEDURE
4–7 Days HOSPITAL STAY
>95% cure SUCCESS RATE
4–6 Weeks RECOVERY

What is Retroperitoneal Lymph Node Dissection (RPLND)?

RPLND is the surgical removal of the retroperitoneal lymph nodes — the primary landing zone for testicular cancer metastasis — through a midline abdominal incision. It is indicated for clinical Stage II NSGCT, residual retroperitoneal masses after chemotherapy (post-chemo RPLND), and selected Stage I high-risk NSGCT. RPLND provides accurate staging, removes potentially viable or malignant residual disease, and is curative for lymph node-confined disease. The procedure is performed under general or spinal anaesthesia with a hospital stay of 4–7 Days. Success rates reach >95% cure in appropriately selected patients at experienced centres.

Patients with clinical Stage II NSGCT, residual retroperitoneal masses post-chemotherapy, or selected high-risk Stage I NSGCT opting for active treatment over surveillance. Patients must be adequately fit for anaesthesia and free from active systemic infection before proceeding.

How the Procedure Works

1

Incision & Exposure

A midline incision from xiphisternum to pubis provides access to the entire retroperitoneum.

2

Template Dissection

The retroperitoneal template is dissected systematically from the renal vessels superiorly to the iliac bifurcation inferiorly.

3

Nerve Identification & Preservation

The postganglionic sympathetic fibres controlling ejaculation are identified descending from L1–L4 paravertebral ganglia and preserved.

4

Post-Chemotherapy Dissection

PC-RPLND is technically more demanding due to fibrosis and vascular adherence from chemotherapy response.

5

Drain & Closure

The retroperitoneum is irrigated and haemostasis confirmed. A closed suction drain is placed in the retroperitoneum; wound closed.

Outcomes

3–5 HoursDURATION
4–7 DaysHOSPITAL STAY
>95% cureSUCCESS RATE
4–6 WeeksFULL RECOVERY

Who Needs This Treatment?

  • Men with clinical stage II non-seminoma with retroperitoneal lymph node involvement.
  • Those with residual retroperitoneal masses after cisplatin-based chemotherapy for testicular GCT.
  • Patients with growing teratoma syndrome — enlarging retroperitoneal masses despite falling markers.
  • Men with late relapse non-seminoma where salvage chemotherapy has been completed.
  • Those with stage I non-seminoma who choose RPLND over surveillance or chemotherapy.
  • Patients with retroperitoneal masses from seminoma after chemotherapy where viable disease is suspected.
"

"RPLND is a technically demanding but life-saving operation for testicular cancer. In experienced hands, it cures lymph node disease with minimal morbidity and preserves the quality of life that young patients deserve."

— — Dr. Vipin Reddy, Consultant Urologist, Andrologist & Renal Transplant Surgeon

Common Questions

Frequently Asked

Not sure which treatment is right for you?

Book a consultation with Dr. Vipin Reddy and get a personalised treatment plan.

WhatsApp Book Now Directions

Language